Moderna Stock Price and Forecast: MRNA may fall to $188 or $157
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get Premium without limits for only $9.99 for the first month
Access all our articles, insights, and analysts.
UNLOCK OFFER- Moderna in continuation pattern.
- Moderna stock has been hammered in November.
- MRNA shares are down nearly 30% this month.
Moderna (MRNA) stock rallied just over 3% on Wednesday in a continuation of recent small gains seen after the tumultuous hammering the stock has suffered this month. Moderna shares are down 27% over the last month despite recovering somewhat this week, up 6% now. Moderna is still snapping back after stretching too far during the pandemic. The pace of earnings growth has slowed despite the company exploding due to the coronavirus pandemic. Vaccine uptake has likely peaked, and revenue growth slowing will see a reevaluation of the underlying share price. This is what is currently happening.
Moderna (MRNA) stock news
While many are arguing the development of antiviral pills is what is hurting Moderna's share price the most, we actually feel it was the weak earnings report. This highlighted a few things. Number one: Moderna is way too reliant on one stream of revenue, that of a covid vaccine. It does have numerous other candidates in trial stages, but only a few have reached phase-3 trials. It takes years for treatments to go through stage trials. Covid did see this process speed up, but it will be back to multiple-year development timelines from now on. What the earnings highlighted the most was a revenue growth slowdown. Once that showed up, it was inevitable that investors would reassess and rebalance their Moderna holdings.
Just in case you are not aware, other headwinds exist. These include the development of antiviral treatments for covid by both Pfizer (PFE) and Merck (MRK) to continuing haggles, which may turn legal, between Moderna and the US government over intellectual property rights for the development of Moderna's covid vaccine.
Moderna (MRNA) stock forecast
The move remains in our view a consolidation of recent losses. A consolidation means a continuation phase is likely, and so a break lower is the most probable outcome. Only breaking the strong resistance from $255 to $265 will change our view. This is the 200-day moving average and the yearly volume-weighted average price (VWAP), so it is a strong resistance to break above. Instead, we are looking for a break lower to $188.41 and then $157, where it will be time to reevalaute the argument.
MRNA 1-day chart
- Moderna in continuation pattern.
- Moderna stock has been hammered in November.
- MRNA shares are down nearly 30% this month.
Moderna (MRNA) stock rallied just over 3% on Wednesday in a continuation of recent small gains seen after the tumultuous hammering the stock has suffered this month. Moderna shares are down 27% over the last month despite recovering somewhat this week, up 6% now. Moderna is still snapping back after stretching too far during the pandemic. The pace of earnings growth has slowed despite the company exploding due to the coronavirus pandemic. Vaccine uptake has likely peaked, and revenue growth slowing will see a reevaluation of the underlying share price. This is what is currently happening.
Moderna (MRNA) stock news
While many are arguing the development of antiviral pills is what is hurting Moderna's share price the most, we actually feel it was the weak earnings report. This highlighted a few things. Number one: Moderna is way too reliant on one stream of revenue, that of a covid vaccine. It does have numerous other candidates in trial stages, but only a few have reached phase-3 trials. It takes years for treatments to go through stage trials. Covid did see this process speed up, but it will be back to multiple-year development timelines from now on. What the earnings highlighted the most was a revenue growth slowdown. Once that showed up, it was inevitable that investors would reassess and rebalance their Moderna holdings.
Just in case you are not aware, other headwinds exist. These include the development of antiviral treatments for covid by both Pfizer (PFE) and Merck (MRK) to continuing haggles, which may turn legal, between Moderna and the US government over intellectual property rights for the development of Moderna's covid vaccine.
Moderna (MRNA) stock forecast
The move remains in our view a consolidation of recent losses. A consolidation means a continuation phase is likely, and so a break lower is the most probable outcome. Only breaking the strong resistance from $255 to $265 will change our view. This is the 200-day moving average and the yearly volume-weighted average price (VWAP), so it is a strong resistance to break above. Instead, we are looking for a break lower to $188.41 and then $157, where it will be time to reevalaute the argument.
MRNA 1-day chart
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.